Clinical Trials Logo

Clinical Trial Details — Status: Withdrawn

Administrative data

NCT number NCT01776892
Other study ID # Dupuytren's 001
Secondary ID
Status Withdrawn
Phase Phase 3
First received January 17, 2013
Last updated April 4, 2014
Start date May 2013
Est. completion date March 2014

Study information

Verified date April 2014
Source University of Alberta
Contact n/a
Is FDA regulated No
Health authority Canada: Health Canada
Study type Interventional

Clinical Trial Summary

Dupuytren's disease results in deformity of the hand and this can lead to trouble with daily activities. Treatment traditionally involves cutting out diseased tissue, however this can cause damage to important structures in the hand and results in large scars.

Needle aponeurotomy and collagenase injections are newer treatments that are thought to be safer. These treatments allow quicker return to function. One drawback is that Dupuytren's deformity may return more quickly than when all diseased tissue is surgically cut out.

This research study is designed to compare the effectiveness of needle aponeurotomy and collagenase injection for Dupuytren's disease. This study will determine which procedure gives the best results- either needle aponeurotomy, collagenase injection, or both procedures in combination. Participants will be evaluated to see how they do in the long term.


Description:

Dupuytren's disease is a benign proliferative disorder of the palmar fascia. It results in progressive thickening and contracture of fibrous bands on the volar surface of the palm and fingers as a result of excessive myofibroblast activity. Patients develop longitudinal cords which may lead to progressive joint contractures. Dupuytren's disease limits hand function and can diminish quality of life.

The most commonly used technique for treatment is open limited fasciectomy. The cumulative complication rate ranges from 14-67% and includes nerve division (2-5%), infection (4-12%), neurapraxia (0.4-52%), and regional pain syndrome (2-13%). The recurrence rate of Dupuytren's disease after fasciectomy is approximately 50% at 5 years.

Recently, interest in needle aponeurotomy and collagenase clostridium histolyticum injection have increased as alternative treatment modalities for Dupuytren's disease. Both procedures can be performed in an outpatient clinic, have limited downtime, allow earlier return to work, and are associated with significantly fewer serious complications than open fasciectomy. Needle aponeurotomy and collagenase injection are less invasive than fasciectomy, however they are associated with higher rates of disease recurrence.

Numerous studies investigating the effectiveness and safety of needle aponeurotomy and collagenase injection studies have been published. To date, there is no published literature about the use of these techniques in combination for the treatment of Dupuytren's disease. The investigators propose to follow the patient population of a single surgeon performing needle aponeurotomy in combination with collagenase injection to determine the effectiveness of this combination treatment. Patients treated with combination treatment will be compared to patients treated with a single modality- either needle aponeurotomy or collagenase injection.

Patients will be assessed pre and post operatively to evaluate functional status and the degree of joint contracture. Patient satisfaction, adverse events, recurrence, and repeat treatment rates will also be determined.


Recruitment information / eligibility

Status Withdrawn
Enrollment 0
Est. completion date March 2014
Est. primary completion date March 2014
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- 18 years of age or older

- Metacarpophalangeal joint contracture between 20-100 degrees OR proximal interphalangeal joint contracture between 20-80 degrees

- Positive table top test, defined as the inability to simultaneously place the affected finger and palm flat on a table

Exclusion Criteria:

- Use of an anticoagulant within 7 days before the beginning of the study, excluding aspirin

- Bleeding disorder

- Recent stroke

- Allergy to collagenase

- A chronic muscular, neurologic, or neuromuscular disorder affecting the hands

- Previous treatment of the affected joint within 90 days before the beginning of the study

- Use of a tetracycline derivative within 14 days before the beginning of the study

- Pregnancy

- Breast feeding

- Premenopausal woman, not using contraception

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
Collegenase injection
Collagenase clostridium histolyticum will be used to treat participants in this arm of the study. Affected cords will be treated with 1-3 collagenase injections at 4 week intervals, based on clinical response of the contracture. Cords will be treated until motion of the joint is within 0-5 degrees of normal, for up to 3 total injections. Metacarpophalangeal cords will be injected with 0.58mg (10 000 units) of collagenase in 0.25ml of sterile diluent. Proximal interphalangeal cords will be injected with 0.58mg (10 000 units) of collagenase in 0.20ml of sterile diluent.
Procedure:
Needle aponeurotomy
Percutaneous needle aponeurotomy will be performed using an 18 gauge needle. The needle is inserted through the skin into the Dupuytren's cord. The needle is moved very slowly through the cord until complete rupture of the cord is obtained.

Locations

Country Name City State
Canada Royal Alexandra Hospital Edmonton Alberta

Sponsors (1)

Lead Sponsor Collaborator
University of Alberta

Country where clinical trial is conducted

Canada, 

References & Publications (5)

Badalamente MA, Hurst LC, Hentz VR. Collagen as a clinical target: nonoperative treatment of Dupuytren's disease. J Hand Surg Am. 2002 Sep;27(5):788-98. — View Citation

Badalamente MA, Hurst LC. Enzyme injection as nonsurgical treatment of Dupuytren's disease. J Hand Surg Am. 2000 Jul;25(4):629-36. — View Citation

Gilpin D, Coleman S, Hall S, Houston A, Karrasch J, Jones N. Injectable collagenase Clostridium histolyticum: a new nonsurgical treatment for Dupuytren's disease. J Hand Surg Am. 2010 Dec;35(12):2027-38.e1. doi: 10.1016/j.jhsa.2010.08.007. — View Citation

Hurst LC, Badalamente MA, Hentz VR, Hotchkiss RN, Kaplan FT, Meals RA, Smith TM, Rodzvilla J; CORD I Study Group. Injectable collagenase clostridium histolyticum for Dupuytren's contracture. N Engl J Med. 2009 Sep 3;361(10):968-79. doi: 10.1056/NEJMoa0810866. — View Citation

van Rijssen AL, ter Linden H, Werker PM. Five-year results of a randomized clinical trial on treatment in Dupuytren's disease: percutaneous needle fasciotomy versus limited fasciectomy. Plast Reconstr Surg. 2012 Feb;129(2):469-77. doi: 10.1097/PRS.0b013e31823aea95. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Degree of joint contracture post treatment The degree of the participant's Dupuytren's disease joint contracture after treatment will be measured by a physical therapist at each of the participant's follow up appointments. 5 years post treatment No
Secondary Change in joint range of motion The participant's range of motion in their joint affected by Dupuytren's disease will be measured by a physical therapist prior to treatment and following treatment at each of the participant's follow up appointments. Baseline and 5 years post treatment No
See also
  Status Clinical Trial Phase
Recruiting NCT03155854 - The Effects of Prophylactic Limited Palmar Fasciectomy on Surgical Outcomes and Scarring N/A
Active, not recruiting NCT03192020 - Trial Comparing Treatment Strategies in Dupuytren's Contracture Phase 4
Recruiting NCT05300893 - Effectiveness of Night Splinting After Percutaneous Needle Fasciotomy in Dupuytren's Contracture N/A
Completed NCT02647619 - Dupuytren´s Disease Study. Primary Disease, MCP Joint, Xiapex, PNF Phase 4
Recruiting NCT01184586 - Dupuytren's Disease and Extracorporeal Shockwave Therapy (DupuyShock-2010) Phase 2
Recruiting NCT04122313 - Post-contracture Release Radiation for Dupuytren's Disease
Completed NCT02983162 - Is wGRS Associated With DD Recurrence?
Completed NCT01923103 - Natural Disease Progress of Dupuytren Disease
Enrolling by invitation NCT03982719 - Comparing the Effectiveness of Two Post-fasciectomy Rehabilitation Protocols in Patients With Dupuytren's Disease N/A
Not yet recruiting NCT04907812 - The Role of Tranexamic Acid in Reducing Post Operative Hand Edema After Hand and Wrist Surgery Phase 4
Withdrawn NCT03031080 - BOND Study: the Benefit Of Night Splinting in Dupuytrens' N/A
Completed NCT04874870 - Effectiveness of Splinting After Collagenase Injection Phase 3
Active, not recruiting NCT03407820 - Different Sutures in Hand Surgery N/A
Recruiting NCT03000114 - Collagenase Injection vs Percutaneous Needle Aponeurotomy for Dupuytren's Disease Phase 4
Recruiting NCT05440240 - Percutaneous Needle Fasciotomy +/- Corticosteroid Injection for Dupuytren's Contracture Phase 4
Completed NCT03331926 - Collagenase is a Common Treatment of MCP and PIP Joint Contractures in Dupuytrens Disease
Active, not recruiting NCT03741764 - Treatment of Dupuytren's Disease With Minimal Invasive Surgery and VIVOSORB® Resorbable Implant Device N/A
Completed NCT01876498 - Registry of Patient With M. Dupuytren and Validation of the Brief MHQ N/A
Completed NCT03868449 - Question Prompt List for Common Hand Conditions N/A
Completed NCT03573765 - Epidemiology and Outcomes of Upper Limb Surgery: Analysis of Routine Data